# The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics

> **NCT04406896** · PHASE1 · COMPLETED · sponsor: **Viatris Innovation GmbH** · enrollment: 24 (actual)

## Conditions studied

- Healthy Subjects
- Hepatic Impairment

## Interventions

- **DRUG:** Selatogrel

## Key facts

- **NCT ID:** NCT04406896
- **Lead sponsor:** Viatris Innovation GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-22
- **Primary completion:** 2020-10-23
- **Final completion:** 2020-10-23
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04406896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04406896, "The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04406896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*